Abstract
In recent years, the use of biologic drugs has greatly changed the therapy of psoriasis and psoriatic arthritis, but they have some adverse effects. In particular, skin lesions induced by anti-tumor necrosis factor (TNF) and anti-interleukin (IL) 12/23 drug (ustekinumab) have been reported with an increased incidence, highlighting the importance of the skin as a major target of the side effects of these drugs. There is a wide spectrum of skin lesions of different morphology and etiology that includes skin lesions directly related to drug administration, the development of cutaneous immune-mediated conditions and cutaneous infections. The aim of this review is to revisit the literature data on inflammatory/infectious skin adverse effects of biologies both anti-TNF-α inhibitors and anti-IL 12/23 antagonists and to report and update our personal data on inflammatory/infectious side effects in patients with psoriasis/psoriatic arthritis treated with biologics.
| Original language | English |
|---|---|
| Pages (from-to) | 311-316 |
| Number of pages | 6 |
| Journal | Giornale Italiano di Dermatologia e Venereologia |
| Volume | 149 |
| Issue number | 3 |
| Publication status | Published - 2014 |
Keywords
- Biological products
- Drug-related side effects and adverse reactions
- Psoriasis
ASJC Scopus subject areas
- Dermatology